DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
DOCS gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. DOCS gets an excellent profitability rating and is at the same time showing great financial health properties. DOCS is growing strongly while it is still valued neutral. This is a good combination! This makes DOCS very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
DOCS had a positive operating cash flow in the past year.
In the past 5 years DOCS has always been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS has a Return On Assets of 17.65%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has a better Return On Equity (20.62%) than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 17.07%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.51%.
The 3 year average ROIC (14.17%) for DOCS is below the current ROIC(17.07%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROIC | 17.07% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
The Profit Margin of DOCS (39.13%) is better than 100.00% of its industry peers.
DOCS's Profit Margin has improved in the last couple of years.
DOCS has a better Operating Margin (40.34%) than 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 90.20%, DOCS belongs to the best of the industry, outperforming 97.14% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DOCS is still creating some value.
Compared to 1 year ago, DOCS has more shares outstanding
The number of shares outstanding for DOCS has been increased compared to 5 years ago.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
DOCS has an Altman-Z score of 37.63. This indicates that DOCS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 37.63, DOCS belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.63 |
ROIC/WACC1.71
WACC9.96%
2.3 Liquidity
A Current Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a Current ratio of 6.97. This is amongst the best in the industry. DOCS outperforms 94.29% of its industry peers.
A Quick Ratio of 6.97 indicates that DOCS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.97, DOCS belongs to the top of the industry, outperforming 94.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.42% over the past year.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
DOCS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.97%.
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
3.2 Future
Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.53% on average per year.
Based on estimates for the next years, DOCS will show a quite strong growth in Revenue. The Revenue will grow by 10.57% on average per year.
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.51%
Revenue Next 5Y10.57%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 40.66, which means the current valuation is very expensive for DOCS.
77.14% of the companies in the same industry are more expensive than DOCS, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.82. DOCS is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 39.67, which means the current valuation is very expensive for DOCS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DOCS is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, DOCS is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.66 | ||
| Fwd PE | 39.67 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 65.71% of the companies listed in the same industry.
65.71% of the companies in the same industry are more expensive than DOCS, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.28 | ||
| EV/EBITDA | 37.89 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)16.36
PEG (5Y)0.51
EPS Next 2Y7.75%
EPS Next 3Y10.11%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.33
-1.42 (-2.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners93.81%
Inst Owner Change0.45%
Ins Owners2.25%
Ins Owner Change-2.03%
Market Cap10.74B
Analysts76.15
Price Target64.54 (12.58%)
Short Float %3.73%
Short Ratio2.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.65%
Min EPS beat(2)30.62%
Max EPS beat(2)36.67%
EPS beat(4)4
Avg EPS beat(4)26.68%
Min EPS beat(4)15.86%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)24.85%
EPS beat(12)12
Avg EPS beat(12)22.9%
EPS beat(16)16
Avg EPS beat(16)34.8%
Revenue beat(2)2
Avg Revenue beat(2)4.77%
Min Revenue beat(2)1.38%
Max Revenue beat(2)8.16%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)6
Avg Revenue beat(8)2.85%
Revenue beat(12)8
Avg Revenue beat(12)1.88%
Revenue beat(16)12
Avg Revenue beat(16)3.35%
PT rev (1m)2.89%
PT rev (3m)-13.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.02%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-2.78%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.66 | ||
| Fwd PE | 39.67 | ||
| P/S | 18.84 | ||
| P/FCF | 40.28 | ||
| P/OCF | 39.32 | ||
| P/B | 9.92 | ||
| P/tB | 10.84 | ||
| EV/EBITDA | 37.89 |
EPS(TTM)1.41
EY2.46%
EPS(NY)1.45
Fwd EY2.52%
FCF(TTM)1.42
FCFY2.48%
OCF(TTM)1.46
OCFY2.54%
SpS3.04
BVpS5.78
TBVpS5.29
PEG (NY)16.36
PEG (5Y)0.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.65% | ||
| ROE | 20.62% | ||
| ROCE | 20.77% | ||
| ROIC | 17.07% | ||
| ROICexc | 98.29% | ||
| ROICexgc | 186.54% | ||
| OM | 40.34% | ||
| PM (TTM) | 39.13% | ||
| GM | 90.2% | ||
| FCFM | 46.76% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexcg growth 3Y3.35%
ROICexcg growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 1.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.5% | ||
| Profit Quality | 119.52% | ||
| Current Ratio | 6.97 | ||
| Quick Ratio | 6.97 | ||
| Altman-Z | 37.63 |
F-Score9
WACC9.96%
ROIC/WACC1.71
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%52%
EPS Next Y2.49%
EPS Next 2Y7.75%
EPS Next 3Y10.11%
EPS Next 5Y17.53%
Revenue 1Y (TTM)19.97%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%17.14%
Revenue Next Year10.68%
Revenue Next 2Y10.59%
Revenue Next 3Y10.51%
Revenue Next 5Y10.57%
EBIT growth 1Y33.93%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year12.42%
EBIT Next 3Y11.62%
EBIT Next 5Y11.91%
FCF growth 1Y49.61%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y48.44%
OCF growth 3Y29.24%
OCF growth 5Y59.83%